ASDr. Ahmed ShihabConsultant Anesthesiologist – Baghdad عربي

GLP-1 agonists and anesthesia: what changed?

For residents and anesthesia technicians

Summary:
  • These drugs slow gastric emptying, so content may remain in the stomach despite standard fasting.
  • The 2023 ASA guidance recommended holding the weekly dose for a week and the oral dose for a day before the procedure.
  • The 2024 guidance from five societies lets most patients continue, with a liquid-only diet for 24 hours in those at higher risk.
  • Day-of-surgery assessment for gastrointestinal symptoms is mandatory for everyone; gastric ultrasound helps when in doubt.

The drugs concerned

Generic nameBrand names
SemaglutideOzempic, Wegovy, Rybelsus (oral)
Tirzepatide (GIP/GLP-1)Mounjaro, Zepbound
LiraglutideVictoza, Saxenda
DulaglutideTrulicity

Why does it matter to anesthesiologists?

These drugs delay gastric emptying and cause nausea, vomiting and bloating, although these symptoms usually ease with long-term use. Their labels have been updated to mention rare reports of pulmonary aspiration of gastric contents in patients who underwent general anesthesia or deep sedation despite fasting, and who were found to have residual gastric content [1]. On the other hand, there are so far no randomised trials that settle the size of this risk [1].

How did the recommendations evolve?

2023: hold before the procedure

In 2023 the American Society of Anesthesiologists (ASA) recommended holding the injectable form for a week and the oral form for a day before any procedure requiring anesthesia [2]. This led to many cancellations and postponements [2].

2024: continue for most patients

Joint guidance from five societies (ASA, AGA, ASMBS, ISPCOP and SAGES) states that most patients can continue the drug before elective surgery, and that those at highest risk of gastrointestinal effects should keep to liquids only for 24 hours before the procedure [3]. The document stresses that it is consensus-based "guidance", not a guideline built on strong evidence [4].

2026: one international direction, different details

A comparative review of international guidelines published between 2023 and 2026 found that four of five recommend continuing the drug with modified fasting, but the details of that modification remain disputed [5].

Who is the higher-risk patient?

  • The patient in the dose-escalation phase, which is more strongly linked to delayed gastric emptying than the maintenance phase [3].
  • The patient on a high dose [3].
  • Nausea, vomiting, abdominal pain, bloating or constipation [6].
  • Other conditions that slow the gut, such as gastroparesis or Parkinson's disease [6].

What do we do in practice?

  1. Assess early: well before surgery so the plan can be adjusted, with a shared decision between patient, surgeon, anesthesiologist and prescriber [4].
  2. Modify the diet: liquids only for 24 hours before the procedure when delayed emptying is suspected, as in bowel preparation for colonoscopy [6].
  3. On the day: ask every patient about gastrointestinal symptoms [7], and use gastric ultrasound when needed to confirm [1].
  4. If doubt remains: consider rapid-sequence induction (RSI) with intubation [2], or postpone the procedure in rare cases [8].
Stopping the drug is not cost-free: glucose may rise, and the patient returns to the escalation phase with its symptoms. That is why current thinking balances aspiration risk against the drug's benefit [3].

References

  1. The Medical Letter. In Brief: New FDA Warning of Pulmonary Aspiration with GLP-1 Receptor Agonists. Med Lett Drugs Ther. 2024;66(1718):201-2. doi:10.58347/tml.2024.1718a
  2. MDedge. GLP-1 RAs Safe in the Perioperative Period: New Guidance (Clinical Gastroenterology and Hepatology, 2024).
  3. ASA, AGA, ASMBS, ISPCOP, SAGES. Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period. Press release, EurekAlert, Oct 2024.
  4. Kindel TL, Wang AY, Wadhwa A, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Obes Relat Dis. 2024. doi:10.1016/j.soard.2024.08.033
  5. Moore T, Ramsahoye B. Perioperative management of patients taking GLP-1 receptor agonists: a comparative review of international clinical guidelines. Saudi J Anaesth. 2026. doi:10.4103/sja.sja_314_26
  6. Kindel TL, et al. Clin Gastroenterol Hepatol. 2024. doi:10.1016/j.cgh.2024.10.003 (summary: MDedge).
  7. Multisociety guidance 2024 – day-of-surgery assessment of all patients (summary: Links Medicus, Nov 2024).
  8. Technology Networks / EurekAlert. Guidance on safe use of GLP-1 during the perioperative period. 2024.

Educational article for healthcare professionals. Clinical decisions rest with the anesthesiologist responsible for the patient and their hospital protocols.

Frequently asked questions

Should Ozempic or Mounjaro be stopped before anesthesia?

Not always. The 2024 multisociety guidance allows most patients to continue, with liquids only for 24 hours before surgery for those at higher risk; the decision is made jointly by the patient, the anesthesiologist and the prescriber.

Is standard fasting enough for patients on these drugs?

It may not be, because they slow gastric emptying. That is why every patient is assessed on the day of surgery, and gastric ultrasound is used when in doubt.

AS

Written and medically reviewed by Dr. Ahmed Shihab
Consultant Anesthesiologist & Intensivist – Arab Board 2014 · Profile
Last reviewed: 2026-11-07